Business
ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026
Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.https://www.sec.gov/ix?doc=/Archives/edgar/data/0001160420/000168316826003957/adia_i10q-033126.htmTo view an...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.","length":387,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":291,"url":"https://media.zenfs.com/en/newsfile_64/d34954da8c71c560f8782bc11c870124"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lFJNIrgqufGym8VuQi1fWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwOA--/https://media.zenfs.com/en/newsfile_64/d34954da8c71c560f8782bc11c870124","width":550,"height":291},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/HdJN6OFjehfNiFCgUfHymQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMzOQ--/https://media.zenfs.com/en/newsfile_64/d34954da8c71c560f8782bc11c870124","width":550,"height":291}},"href":"https://images.newsfilecorp.com/files/10520/297620_adia_image1.jpg","hrefExternal":true},{"type":"text","content":"https://www.sec.gov/ix?doc=/Archives/edgar/data/0001160420/000168316826003957/adia_i10q-033126.htmTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/297620_adia_image1.jpg","length":225,"tagName":"p","attribs":{}},{"type":"text","content":"Key Highlights for Q1 2026 (compared to Q1 2025):","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total Revenue increased 146% to $176,275 from $71,764, reflecting strong demand and successful diversification of revenue streams.","length":130,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Medical Procedures Revenue grew 48% to $104,850 from $70,700, demonstrating continued patient adoption of ADIA's innovative regenerative therapies.","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Biologics Sales delivered $69,775 in new revenue (compared to $0 in the prior-year period), marking the successful commercialization and rapid traction of the Company's high-margin biologic products.","length":203,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross...